Europeopioid Induced Constipation Drug Market Forecast 2017-2025

Europeopioid Induced Constipation Drug Market Forecast 2017-2025

  • August 2017 •
  • 52 pages •
  • Report ID: 5039886 •
  • Format: PDF
KEY FINDINGS
The Europe opioid constipation drug market is expected to grow at a CAGR of 4.00% during the forecast period of 2017-2025. The market value is predicted to increase from $896.3 million in 2016 and reach up to $1273.34 million by 2025.

MARKET INSIGHTS
The Europe opioid constipation drug market is mainly driven by the increasing opioids prescription in the region. The market can be segmented into two criteria. First is the market by drug type that includes drugs such as naloxegol, methyl naltrexone bromide, lubiprostone, others.of these, Lubiprostone is currently the most popular drug type in the region.

The second market criteria is on the basis of the type of prescription that includes over the counter drugs and branded or generic prescribed drugs. The over the counter drugs are more popular as compared to the prescribed ones due to their ease of availability.

COMPETITIVE INSIGHTS
Some of the major companies in the market include:
• Pfizer
• Daiichi Sankyo Co Ltd
• Progenics Pharmaceuticals Inc
• Nektar Therapeutics
• Allergan Plc
• Purdue Pharma L.P.
• Valeant Pharmaceuticals International
• Cosmo Pharmaceuticals Sa
• Daewoong Pharmaceutical Co., Ltd.
• Theravance Biopharma Inc
• C.B. Fleet Company, Inc.